Related Experiment Videos
Ovarian cancer gene therapy
D L Tait1, P S Obermiller, R A Jensen
1Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Hematology/Oncology Clinics of North America
|July 31, 1998
Summary
Gene therapy using LXN-BRCA1sv, a BRCA1 splice variant, effectively reduced ovarian cancer tumor burden in mice and showed minimal toxicity in human trials. The treatment demonstrated stability and expression in patients, with 8 of 12 achieving stable disease.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- BRCA1 gene mutations are linked to increased ovarian cancer risk.
- Retroviral vectors are being explored for targeted gene delivery in cancer therapy.
- LXN-BRCA1sv represents a normal splice variant of the BRCA1 gene for therapeutic use.
Purpose of the Study:
- To evaluate the efficacy and safety of retroviral-mediated BRCA1 gene therapy (LXN-BRCA1sv) in preclinical models and a Phase I clinical trial for ovarian cancer.
- To assess the vector's stability, tissue transfer, and expression in patients with recurrent or persistent epithelial ovarian cancer.
Main Methods:
- Preclinical testing in mouse models to assess tumor reduction and toxicity.
- Phase I clinical trial involving 12 patients with recurrent/persistent epithelial ovarian cancer receiving intraperitoneal LXN-BRCA1sv vector.
- Monitoring for toxicity, vector stability, gene expression, and clinical response (stable disease).
Main Results:
- LXN-BRCA1sv demonstrated significant tumor burden reduction and minimal toxicity in mouse models.
- In the Phase I trial, the gene therapy showed minimal toxicity, with manageable side effects like fever and sterile peritonitis.
- The vector exhibited stability and expression in patient tissues, with 8 out of 12 patients achieving stable disease.
Conclusions:
- The peritoneal cavity may be a suitable site for gene therapy delivery in ovarian cancer.
- Retroviral-mediated delivery of LXN-BRCA1sv is a potentially safe and effective therapeutic strategy for recurrent or persistent epithelial ovarian cancer.
- Further investigation into BRCA1 gene therapy for ovarian cancer is warranted based on these promising preliminary results.